Antisense and RNAi therapeutics Market Trends

• Vendors are establishing strategic partnerships and collaborations to enable the exchange of technology, intellectual property, to expediate the development in RNA therapeutics such as antisense and RNAi therapeutics. Vendors are directing their efforts toward addressing the primary hurdles in RNAi and antisense therapeutics related to efficient delivery of therapeutics to target cells or tissues.
  
• Advances in nanoparticle technology, lipid-based carriers, and other delivery systems have improved the stability, specificity, and uptake of RNA-based therapeutics, allowing them to reach their intended targets more effectively. For instance, in 2021, US FDA approved Leqvio (inclisiran) injection that uses lipid nanoparticle ALN-PCS, for SiRNA delivery.
  
• Moreover, recent advances in antisense oligonucleotides technology have enabled the development of therapies for genetic disorders, neurological diseases, and cancer. For instance, four antisense oligonucleotides were approved by US FDA in 2023, intended for the treatment of neurological and genetic disorders. These included Qalsody for amyotrophic lateral sclerosis, Izervay for geographic atrophy, Rivfloza injection for primary hyperoxaluria, and WAINUA for polyneuropathy of hereditary amyloidosis.
  
• Furthermore, vendors are also targeting the potential for combining RNAi/antisense therapeutics with other treatment modalities to improve patient outcomes. These combination therapies, including the combination vaccines and drugs, aims to overcome challenges related to drug resistance through targeting multiple disease mechanisms concurrently.